$4.74
2.87% yesterday
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US56400P7069
Symbol
MNKD
Sector
Industry

MannKind Corporation Stock price

$4.74
-0.41 7.96% 1M
-1.75 26.96% 6M
-1.69 26.28% YTD
+0.43 9.98% 1Y
+0.74 18.50% 3Y
+3.76 381.22% 5Y
-20.76 81.41% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.14 2.87%
ISIN
US56400P7069
Symbol
MNKD
Sector
Industry

Key metrics

Market capitalization $1.44b
Enterprise Value $1.40b
P/E (TTM) P/E ratio 51.80
EV/FCF (TTM) EV/FCF 43.19
EV/Sales (TTM) EV/Sales 4.90
P/S ratio (TTM) P/S ratio 5.04
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 43.50%
Revenue (TTM) Revenue $285.50m
EBIT (operating result TTM) EBIT $68.68m
Free Cash Flow (TTM) Free Cash Flow $32.42m
Cash position $197.26m
EPS (TTM) EPS $0.09
P/E forward 25.52
P/S forward 4.50
EV/Sales forward 4.37
Short interest 10.02%
Show more

Is MannKind Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

MannKind Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a MannKind Corporation forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a MannKind Corporation forecast:

Buy
100%

Financial data from MannKind Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
286 286
43% 43%
100%
- Direct Costs 77 77
22% 22%
27%
209 209
53% 53%
73%
- Selling and Administrative Expenses 85 85
4% 4%
30%
- Research and Development Expense 46 46
47% 47%
16%
78 78
373% 373%
27%
- Depreciation and Amortization 8.97 8.97
55% 55%
3%
EBIT (Operating Income) EBIT 69 69
548% 548%
24%
Net Profit 28 28
331% 331%
10%

In millions USD.

Don't miss a Thing! We will send you all news about MannKind Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MannKind Corporation Stock News

Neutral
GlobeNewsWire
26 days ago
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
Positive
Seeking Alpha
about one month ago
MannKind's stock has fluctuated due to Tyvaso DPI's Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI's potential expansion into IPF and MannKind's in-house developments in NTM-LD and IPF present significant growth opportunities despite competitive threats. MannKind's financial health is solid, with strong liq...
Neutral
Seeking Alpha
about one month ago
MannKind Corporation (NASDAQ:MNKD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Corporate Participants Michael Castagna - Chief Executive Officer Chris Prentiss - Chief Financial Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald Faisal Khurshid - Leerink Partners Anish Nikhanj - RBC Capital Markets Andreas Argyrides - Oppenheimer Brandon Folkes - Rodman & ...
More MannKind Corporation News

Company Profile

MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.

Head office United States
CEO Michael Castagna
Employees 407
Founded 1991
Website www.mannkindcorp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today